A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes
Primary Purpose
Diabetes
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Insulclock with feedback
Insulclock without feedback
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes focused on measuring Uncontrolled Type 2 Diabetes, Insulclock, Electronic device, Alarm system
Eligibility Criteria
Inclusion Criteria:
- Age: 18 to 80 years
- Diagnosis of T2D
- Screening HbA1c ≥ 7.5% to ≤ 11%
- Continuous treatment with one or more oral antidiabetic agents, for at least 2 months
- Continuous treatment with daily basal insulin (NPH, glargine U100 or detemir), for at least 2 months, (insulin dose ≤0.5U/Kg/day)
- If patients are on combination therapy of basal insulin and GLP1-RA, the dose of GLP-1 RA should be stable for the past three months.
- Owns a smartphone - Apple iPhone, Samsung Galaxy models
- Signed, informed consent and HIPAA documentation
- Subjects' ability to self-administer insulin, use the device and complete subject reported outcomes instruments
- Subjects' ability & willingness to adhere to and be compliant with study protocol
Exclusion Criteria:
- Refusal or inability to give informed consent to participate in the study
- Subject is currently taking or was treated with glargine U300 insulin, degludec, insulin dose greater than 0.5 U/kg/day during the previous three months
- Subject treated with prandial insulin or premixed formulations during the previous three months
- Impaired renal function as shown by, but not limited to, eGFR < 30 ml/min.
- Muscle weakness or hemiparesis related to previous stroke or myelopathy resulting in incoordination, muscle weakness and inability to use pen device for insulin administration
- History of diabetic ketoacidosis during the previous 6 months
- Clinical evidence of active liver disease, or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 times the upper limit of the normal range
- History of hypoglycemia unawareness
- Pregnancy or lactation
- Known hypersensitivity to insulin glargine or any of the components
- Any malignancy within the last 5 years, except for adequately treated basal or squamous cell carcinoma of the skin or adequately treated cervical carcinoma in situ
- Current drug addiction or current alcohol abuse, or history of substance or alcohol abuse within the last 2 years
- Diagnosis of dementia
- Severe gastrointestinal diseases including gastroparesis
- Cardiac status NYHA III-IV
- Acute infection
- Patients on or planning to receive long term oral or injectable steroid treatment for greater than 10 days
- Patient schedule to undergo general surgery during the next 6 months
- Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with the completion of the study
Sites / Locations
- Emory Clinic, Emory University Hospital (non-CRN), Emory University Hospital Clinical Research Network, Emory University Hospital Midtown, Grady Health System (non-CRN)
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Insulclock with feedback (Group A)
Insulclock without feedback (Group B)
Arm Description
Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
Outcomes
Primary Outcome Measures
Number of Insulin Injection Irregularities.
Number of insulin injection irregularities (omission, mistiming and dosing) will be registered on the Insulclock device, and data will be retrieved during each clinic visit to monitor treatment adherence.
Number of Participants Experiencing Insulclock Device Malfunctions
Number of participants experiencing Insulclock device malfunctions are reported
Secondary Outcome Measures
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc-change) Score.
The amplitude of the score on the DTSQc gives the degree of change in satisfaction while the direction (positive or negative) will provide guidance on the preference of one device over the other. DTSQc contains eight items scored on 7-point scales; scores range from +3 = much more satisfied now to -3 = much less satisfied now, with 0 (midpoint), representing no change.
Change in Diabetes Related Quality of Life (DRQoL) Scores.
DRQoL is a composite score, consisting of a standardized and unweighted Insulin Treatment Experience Questionnaire Score (ITEQ), and Problem Areas in Diabetes (PAID) questionnaire score. ITEQ includes 7 domains: leisure activities (4 items), psychological barriers (2 items), handling (5 items), diabetes control (6 items), dependence (5 items), weight control (3 items), sleep (2 items); + 1 additional item assigned to assess overall satisfaction with current insulin therapy regimen. The PAID contains 20 items that describe negative emotions related to diabetes commonly experienced by patients with diabetes. Each question has five possible answers with a value from 0 to 4, with 0 representing "no problem" and 4 "a serious problem". The scores are added up and multiplied by 1.25, generating a total score between 0 - 100.
Change in Mean HbA1c.
HbA1c is a form of hemoglobin that is measured primarily to identify the three-month average plasma glucose concentration. The test is limited to a three-month average because the lifespan of a red blood cell is four months (120 days). Change in mean HbA1cas will be measure and recorded to monitor glycemic control.
Number of Episodes of Hypoglycemia.
Number of episodes of hypoglycemia will be recorded. For this study, symptomatic hypoglycemia is defined as an event with typical symptoms (i.e., sweating, palpitation, and feeling of hunger) with or without confirmation by plasma glucose <54 mg/dl (3.9 mmol/L).
Number of Episodes of Severe Hypoglycemia.
Number of episodes of severe hypoglycemia will be recorded.Severe hypoglycemia is defined as episodes necessitating assistance and associated with measured plasma glucose < 40 mg/dl (2.2 mmol/L), or with prompt recovery after administration of carbohydrates, glucagon, or other resuscitative actions.
Change in Daily Fasting Glucose Profile Averages.
Daily fasting glucose profile averages will be recorded to monitor glycemic control.
Change in 7-point Self Monitoring of Blood Glucose (SMBG) Profile.
SMBG refers to home blood glucose testing for people with diabetes. 7-point SMBG profile include fasting, before meals, 2 hours after meals, and bedtime.
Change in Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R) Score
The DQLCTQ-R is a 57-item scale that comprises 8 dimensions: physical function, energy/fatigue, health distress, mental health, satisfaction, treatment satisfaction, treatment flexibility, and frequency of symptoms.
Full Information
NCT ID
NCT03224234
First Posted
July 19, 2017
Last Updated
January 4, 2021
Sponsor
Emory University
Collaborators
Insulcoud S.L.
1. Study Identification
Unique Protocol Identification Number
NCT03224234
Brief Title
A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes
Official Title
A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
November 29, 2017 (Actual)
Primary Completion Date
September 18, 2019 (Actual)
Study Completion Date
September 18, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University
Collaborators
Insulcoud S.L.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Poor adherence to insulin regimens is reported in up to two-third of patients with diabetes; thus it is important to identify patients at risk and to develop strategies and tools to increase adherence to prescribed insulin regimens. This study will evaluate the efficacy of Insulclock® - small electronic device to help track date, time and dosage of the last injection, type of insulin used and temperature, with an alarm system to prevent insulin omissions and mistiming.
Detailed Description
Diabetes is arguably the most urgent healthcare challenge of the 21st century. Poor adherence to insulin regimens is reported in up to two-third of patients with diabetes; thus it is important to identify patients at risk and to develop strategies and tools to increase adherence to prescribed insulin regimens. This study will evaluate the efficacy of Insulclock® - small electronic device to help track date, time and dosage of the last injection, type of insulin used and temperature, with an alarm system to prevent insulin omissions and mistiming. The Insulclock's real time memory and alert system are likely to improve treatment adherence, patient's satisfaction, and quality of life measures, which may improve glycemic control in insulin treated patients with Type 2 Diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes
Keywords
Uncontrolled Type 2 Diabetes, Insulclock, Electronic device, Alarm system
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
At midpoint (week 12), patients will be converted to the alternate arm (cross-over design).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
121 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Insulclock with feedback (Group A)
Arm Type
Experimental
Arm Description
Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
Arm Title
Insulclock without feedback (Group B)
Arm Type
Active Comparator
Arm Description
Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
Intervention Type
Device
Intervention Name(s)
Insulclock with feedback
Intervention Description
Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
Intervention Type
Device
Intervention Name(s)
Insulclock without feedback
Intervention Description
Not feedback on insulin administration.
Primary Outcome Measure Information:
Title
Number of Insulin Injection Irregularities.
Description
Number of insulin injection irregularities (omission, mistiming and dosing) will be registered on the Insulclock device, and data will be retrieved during each clinic visit to monitor treatment adherence.
Time Frame
Week 0 through week 24.
Title
Number of Participants Experiencing Insulclock Device Malfunctions
Description
Number of participants experiencing Insulclock device malfunctions are reported
Time Frame
Up to 12 weeks
Secondary Outcome Measure Information:
Title
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc-change) Score.
Description
The amplitude of the score on the DTSQc gives the degree of change in satisfaction while the direction (positive or negative) will provide guidance on the preference of one device over the other. DTSQc contains eight items scored on 7-point scales; scores range from +3 = much more satisfied now to -3 = much less satisfied now, with 0 (midpoint), representing no change.
Time Frame
Baseline, 24 weeks
Title
Change in Diabetes Related Quality of Life (DRQoL) Scores.
Description
DRQoL is a composite score, consisting of a standardized and unweighted Insulin Treatment Experience Questionnaire Score (ITEQ), and Problem Areas in Diabetes (PAID) questionnaire score. ITEQ includes 7 domains: leisure activities (4 items), psychological barriers (2 items), handling (5 items), diabetes control (6 items), dependence (5 items), weight control (3 items), sleep (2 items); + 1 additional item assigned to assess overall satisfaction with current insulin therapy regimen. The PAID contains 20 items that describe negative emotions related to diabetes commonly experienced by patients with diabetes. Each question has five possible answers with a value from 0 to 4, with 0 representing "no problem" and 4 "a serious problem". The scores are added up and multiplied by 1.25, generating a total score between 0 - 100.
Time Frame
Baseline, 24 weeks
Title
Change in Mean HbA1c.
Description
HbA1c is a form of hemoglobin that is measured primarily to identify the three-month average plasma glucose concentration. The test is limited to a three-month average because the lifespan of a red blood cell is four months (120 days). Change in mean HbA1cas will be measure and recorded to monitor glycemic control.
Time Frame
Baseline, 24 weeks
Title
Number of Episodes of Hypoglycemia.
Description
Number of episodes of hypoglycemia will be recorded. For this study, symptomatic hypoglycemia is defined as an event with typical symptoms (i.e., sweating, palpitation, and feeling of hunger) with or without confirmation by plasma glucose <54 mg/dl (3.9 mmol/L).
Time Frame
Week 0 through week 24.
Title
Number of Episodes of Severe Hypoglycemia.
Description
Number of episodes of severe hypoglycemia will be recorded.Severe hypoglycemia is defined as episodes necessitating assistance and associated with measured plasma glucose < 40 mg/dl (2.2 mmol/L), or with prompt recovery after administration of carbohydrates, glucagon, or other resuscitative actions.
Time Frame
Week 0 through week 24.
Title
Change in Daily Fasting Glucose Profile Averages.
Description
Daily fasting glucose profile averages will be recorded to monitor glycemic control.
Time Frame
Week 0 through week 24.
Title
Change in 7-point Self Monitoring of Blood Glucose (SMBG) Profile.
Description
SMBG refers to home blood glucose testing for people with diabetes. 7-point SMBG profile include fasting, before meals, 2 hours after meals, and bedtime.
Time Frame
3 to 5 days prior to randomization, up to 24 weeks.
Title
Change in Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R) Score
Description
The DQLCTQ-R is a 57-item scale that comprises 8 dimensions: physical function, energy/fatigue, health distress, mental health, satisfaction, treatment satisfaction, treatment flexibility, and frequency of symptoms.
Time Frame
Baseline, 24 weeks.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 18 to 80 years
Diagnosis of T2D
Screening HbA1c ≥ 7.5% to ≤ 11%
Continuous treatment with one or more oral antidiabetic agents, for at least 2 months
Continuous treatment with daily basal insulin (NPH, glargine U100 or detemir), for at least 2 months, (insulin dose ≤0.5U/Kg/day)
If patients are on combination therapy of basal insulin and GLP1-RA, the dose of GLP-1 RA should be stable for the past three months.
Owns a smartphone - Apple iPhone, Samsung Galaxy models
Signed, informed consent and HIPAA documentation
Subjects' ability to self-administer insulin, use the device and complete subject reported outcomes instruments
Subjects' ability & willingness to adhere to and be compliant with study protocol
Exclusion Criteria:
Refusal or inability to give informed consent to participate in the study
Subject is currently taking or was treated with glargine U300 insulin, degludec, insulin dose greater than 0.5 U/kg/day during the previous three months
Subject treated with prandial insulin or premixed formulations during the previous three months
Impaired renal function as shown by, but not limited to, eGFR < 30 ml/min.
Muscle weakness or hemiparesis related to previous stroke or myelopathy resulting in incoordination, muscle weakness and inability to use pen device for insulin administration
History of diabetic ketoacidosis during the previous 6 months
Clinical evidence of active liver disease, or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 times the upper limit of the normal range
History of hypoglycemia unawareness
Pregnancy or lactation
Known hypersensitivity to insulin glargine or any of the components
Any malignancy within the last 5 years, except for adequately treated basal or squamous cell carcinoma of the skin or adequately treated cervical carcinoma in situ
Current drug addiction or current alcohol abuse, or history of substance or alcohol abuse within the last 2 years
Diagnosis of dementia
Severe gastrointestinal diseases including gastroparesis
Cardiac status NYHA III-IV
Acute infection
Patients on or planning to receive long term oral or injectable steroid treatment for greater than 10 days
Patient schedule to undergo general surgery during the next 6 months
Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with the completion of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillermo Umpierrez, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Emory Clinic, Emory University Hospital (non-CRN), Emory University Hospital Clinical Research Network, Emory University Hospital Midtown, Grady Health System (non-CRN)
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes
We'll reach out to this number within 24 hrs